Neoadjuvant Immunotherapy to ESCC

NCT04625543 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped insufficient money

Conditions

Esophagus SCC

Interventions

DRUG: Sintilimab Injection plus Paclitaxel and Cisplatin
DRUG: Paclitaxel and Cisplatin

Sponsor

Qilu Hospital of Shandong University